nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—pancreatic cancer	0.228	0.638	CtDrD
Sorafenib—KDR—pancreatic cancer	0.131	1	CbGaD
Sorafenib—kidney cancer—pancreatic cancer	0.129	0.362	CtDrD
Sorafenib—HIPK3—Sunitinib—pancreatic cancer	0.0221	0.0618	CbGbCtD
Sorafenib—MKNK1—Erlotinib—pancreatic cancer	0.0192	0.0539	CbGbCtD
Sorafenib—AURKC—Erlotinib—pancreatic cancer	0.0192	0.0539	CbGbCtD
Sorafenib—FLT3—Erlotinib—pancreatic cancer	0.0139	0.039	CbGbCtD
Sorafenib—MAP3K7—Sunitinib—pancreatic cancer	0.0127	0.0355	CbGbCtD
Sorafenib—AURKC—Sunitinib—pancreatic cancer	0.0127	0.0355	CbGbCtD
Sorafenib—FLT1—Sunitinib—pancreatic cancer	0.0127	0.0355	CbGbCtD
Sorafenib—EPHA6—Erlotinib—pancreatic cancer	0.0123	0.0345	CbGbCtD
Sorafenib—HIPK4—Erlotinib—pancreatic cancer	0.0123	0.0345	CbGbCtD
Sorafenib—STK10—Erlotinib—pancreatic cancer	0.011	0.031	CbGbCtD
Sorafenib—FLT4—Sunitinib—pancreatic cancer	0.0106	0.0297	CbGbCtD
Sorafenib—FGFR1—Sunitinib—pancreatic cancer	0.0106	0.0297	CbGbCtD
Sorafenib—MAP2K5—Erlotinib—pancreatic cancer	0.0101	0.0282	CbGbCtD
Sorafenib—RALBP1—Doxorubicin—pancreatic cancer	0.00949	0.0266	CbGbCtD
Sorafenib—MAP3K19—Erlotinib—pancreatic cancer	0.00924	0.0259	CbGbCtD
Sorafenib—FLT3—Sunitinib—pancreatic cancer	0.00916	0.0257	CbGbCtD
Sorafenib—KDR—Sunitinib—pancreatic cancer	0.00916	0.0257	CbGbCtD
Sorafenib—RET—Sunitinib—pancreatic cancer	0.00916	0.0257	CbGbCtD
Sorafenib—EPHB6—Sunitinib—pancreatic cancer	0.0081	0.0227	CbGbCtD
Sorafenib—HIPK4—Sunitinib—pancreatic cancer	0.0081	0.0227	CbGbCtD
Sorafenib—STK10—Sunitinib—pancreatic cancer	0.00728	0.0204	CbGbCtD
Sorafenib—KIT—Sunitinib—pancreatic cancer	0.00728	0.0204	CbGbCtD
Sorafenib—PDGFRA—Sunitinib—pancreatic cancer	0.00728	0.0204	CbGbCtD
Sorafenib—CSF1R—Sunitinib—pancreatic cancer	0.00728	0.0204	CbGbCtD
Sorafenib—MAP2K5—Sunitinib—pancreatic cancer	0.00662	0.0186	CbGbCtD
Sorafenib—PDGFRB—Sunitinib—pancreatic cancer	0.00662	0.0186	CbGbCtD
Sorafenib—MAP3K19—Sunitinib—pancreatic cancer	0.00609	0.0171	CbGbCtD
Sorafenib—RET—enteric nervous system—pancreatic cancer	0.00444	0.21	CbGeAlD
Sorafenib—UGT1A9—Irinotecan—pancreatic cancer	0.00366	0.0103	CbGbCtD
Sorafenib—UGT1A1—Erlotinib—pancreatic cancer	0.00332	0.0093	CbGbCtD
Sorafenib—UGT1A1—Irinotecan—pancreatic cancer	0.00299	0.0084	CbGbCtD
Sorafenib—ABCC4—Fluorouracil—pancreatic cancer	0.00294	0.00824	CbGbCtD
Sorafenib—ABCC2—Tamoxifen—pancreatic cancer	0.00237	0.00665	CbGbCtD
Sorafenib—ABCC4—Sunitinib—pancreatic cancer	0.00223	0.00626	CbGbCtD
Sorafenib—ABCG2—Tamoxifen—pancreatic cancer	0.00215	0.00601	CbGbCtD
Sorafenib—ABCG2—Erlotinib—pancreatic cancer	0.00182	0.00511	CbGbCtD
Sorafenib—ABCC2—Irinotecan—pancreatic cancer	0.00182	0.00511	CbGbCtD
Sorafenib—Vismodegib—SHH—pancreatic cancer	0.00171	0.756	CrCbGaD
Sorafenib—ABCG2—Irinotecan—pancreatic cancer	0.00165	0.00462	CbGbCtD
Sorafenib—CYP3A7—Tamoxifen—pancreatic cancer	0.00158	0.00444	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.00158	0.00444	CbGbCtD
Sorafenib—ABCG2—Fluorouracil—pancreatic cancer	0.00158	0.00443	CbGbCtD
Sorafenib—CYP2B6—Tamoxifen—pancreatic cancer	0.00151	0.00423	CbGbCtD
Sorafenib—ABCC2—bile duct—pancreatic cancer	0.00151	0.0711	CbGeAlD
Sorafenib—FLT1—umbilical vein—pancreatic cancer	0.00139	0.0654	CbGeAlD
Sorafenib—ABCC2—Docetaxel—pancreatic cancer	0.00134	0.00374	CbGbCtD
Sorafenib—ABCC2—Sunitinib—pancreatic cancer	0.00133	0.00373	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.00122	0.00341	CbGbCtD
Sorafenib—CYP3A7—Irinotecan—pancreatic cancer	0.00122	0.00341	CbGbCtD
Sorafenib—ABCG2—Docetaxel—pancreatic cancer	0.00121	0.00338	CbGbCtD
Sorafenib—ABCG2—Sunitinib—pancreatic cancer	0.0012	0.00337	CbGbCtD
Sorafenib—CYP3A5—Tamoxifen—pancreatic cancer	0.00119	0.00333	CbGbCtD
Sorafenib—KDR—umbilical vein—pancreatic cancer	0.00117	0.0553	CbGeAlD
Sorafenib—CYP2B6—Irinotecan—pancreatic cancer	0.00116	0.00325	CbGbCtD
Sorafenib—ABCC2—bile—pancreatic cancer	0.00116	0.0547	CbGeAlD
Sorafenib—CYP2C8—Tamoxifen—pancreatic cancer	0.00114	0.0032	CbGbCtD
Sorafenib—CYP1A2—Dacarbazine—pancreatic cancer	0.00111	0.00312	CbGbCtD
Sorafenib—CYP3A5—Erlotinib—pancreatic cancer	0.00101	0.00283	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—pancreatic cancer	0.000995	0.00279	CbGbCtD
Sorafenib—CYP2C8—Erlotinib—pancreatic cancer	0.000972	0.00272	CbGbCtD
Sorafenib—CYP2C19—Tamoxifen—pancreatic cancer	0.000959	0.00269	CbGbCtD
Sorafenib—CYP3A5—Irinotecan—pancreatic cancer	0.000913	0.00256	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—pancreatic cancer	0.0009	0.00252	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—pancreatic cancer	0.000892	0.0025	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.000892	0.0025	CbGbCtD
Sorafenib—CYP3A7—Sunitinib—pancreatic cancer	0.000888	0.00249	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.000888	0.00249	CbGbCtD
Sorafenib—CYP1A2—Tamoxifen—pancreatic cancer	0.000885	0.00248	CbGbCtD
Sorafenib—CYP2C8—Fluorouracil—pancreatic cancer	0.000842	0.00236	CbGbCtD
Sorafenib—CYP2C9—Tamoxifen—pancreatic cancer	0.000797	0.00223	CbGbCtD
Sorafenib—ABCB1—Tamoxifen—pancreatic cancer	0.000774	0.00217	CbGbCtD
Sorafenib—CYP1A2—Erlotinib—pancreatic cancer	0.000752	0.00211	CbGbCtD
Sorafenib—CYP2D6—Tamoxifen—pancreatic cancer	0.000729	0.00204	CbGbCtD
Sorafenib—CYP3A5—Docetaxel—pancreatic cancer	0.000669	0.00187	CbGbCtD
Sorafenib—ABCB1—Gemcitabine—pancreatic cancer	0.000666	0.00187	CbGbCtD
Sorafenib—CYP3A5—Sunitinib—pancreatic cancer	0.000666	0.00187	CbGbCtD
Sorafenib—ABCB1—Erlotinib—pancreatic cancer	0.000658	0.00184	CbGbCtD
Sorafenib—CYP1A2—Fluorouracil—pancreatic cancer	0.000652	0.00183	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—pancreatic cancer	0.000633	0.00177	CbGbCtD
Sorafenib—HIPK3—islet of Langerhans—pancreatic cancer	0.000622	0.0294	CbGeAlD
Sorafenib—CYP2D6—Erlotinib—pancreatic cancer	0.00062	0.00174	CbGbCtD
Sorafenib—ABCB1—Irinotecan—pancreatic cancer	0.000594	0.00166	CbGbCtD
Sorafenib—CYP2C9—Fluorouracil—pancreatic cancer	0.000587	0.00165	CbGbCtD
Sorafenib—Regorafenib—KDR—pancreatic cancer	0.000553	0.244	CrCbGaD
Sorafenib—PDGFRA—gall bladder—pancreatic cancer	0.000534	0.0252	CbGeAlD
Sorafenib—RAF1—Topotecan—Irinotecan—pancreatic cancer	0.00053	0.359	CbGdCrCtD
Sorafenib—CYP3A4—Tamoxifen—pancreatic cancer	0.000463	0.0013	CbGbCtD
Sorafenib—HIPK3—pancreas—pancreatic cancer	0.000438	0.0207	CbGeAlD
Sorafenib—ABCB1—Docetaxel—pancreatic cancer	0.000435	0.00122	CbGbCtD
Sorafenib—MKNK2—islet of Langerhans—pancreatic cancer	0.000435	0.0205	CbGeAlD
Sorafenib—ABCB1—Sunitinib—pancreatic cancer	0.000433	0.00121	CbGbCtD
Sorafenib—KIT—gall bladder—pancreatic cancer	0.000427	0.0202	CbGeAlD
Sorafenib—PDGFRB—gall bladder—pancreatic cancer	0.000417	0.0197	CbGeAlD
Sorafenib—CDK7—Topotecan—Irinotecan—pancreatic cancer	0.000402	0.272	CbGdCrCtD
Sorafenib—CYP3A4—Erlotinib—pancreatic cancer	0.000394	0.0011	CbGbCtD
Sorafenib—RALBP1—islet of Langerhans—pancreatic cancer	0.000393	0.0185	CbGeAlD
Sorafenib—ZAK—digestive system—pancreatic cancer	0.000382	0.018	CbGeAlD
Sorafenib—FLT1—islet of Langerhans—pancreatic cancer	0.000374	0.0176	CbGeAlD
Sorafenib—HIPK3—digestive system—pancreatic cancer	0.000374	0.0176	CbGeAlD
Sorafenib—RAF1—islet of Langerhans—pancreatic cancer	0.000372	0.0175	CbGeAlD
Sorafenib—EPHB6—islet of Langerhans—pancreatic cancer	0.000369	0.0174	CbGeAlD
Sorafenib—CYP3A4—Irinotecan—pancreatic cancer	0.000356	0.000998	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—pancreatic cancer	0.000324	0.00091	CbGbCtD
Sorafenib—MKNK2—pancreas—pancreatic cancer	0.000306	0.0144	CbGeAlD
Sorafenib—CYP2D6—Doxorubicin—pancreatic cancer	0.000306	0.000857	CbGbCtD
Sorafenib—UGT1A9—digestive system—pancreatic cancer	0.000293	0.0138	CbGeAlD
Sorafenib—RALBP1—pancreas—pancreatic cancer	0.000276	0.013	CbGeAlD
Sorafenib—PDGFRB—islet of Langerhans—pancreatic cancer	0.000273	0.0129	CbGeAlD
Sorafenib—FLT1—pancreas—pancreatic cancer	0.000263	0.0124	CbGeAlD
Sorafenib—MKNK2—digestive system—pancreatic cancer	0.000261	0.0123	CbGeAlD
Sorafenib—RAF1—pancreas—pancreatic cancer	0.000261	0.0123	CbGeAlD
Sorafenib—CYP3A4—Docetaxel—pancreatic cancer	0.000261	0.000731	CbGbCtD
Sorafenib—CYP3A4—Sunitinib—pancreatic cancer	0.00026	0.000728	CbGbCtD
Sorafenib—MKNK1—digestive system—pancreatic cancer	0.000258	0.0122	CbGeAlD
Sorafenib—RET—digestive system—pancreatic cancer	0.000255	0.012	CbGeAlD
Sorafenib—RALBP1—digestive system—pancreatic cancer	0.000236	0.0111	CbGeAlD
Sorafenib—FLT1—digestive system—pancreatic cancer	0.000224	0.0106	CbGeAlD
Sorafenib—RAF1—digestive system—pancreatic cancer	0.000223	0.0105	CbGeAlD
Sorafenib—STK10—digestive system—pancreatic cancer	0.000212	0.01	CbGeAlD
Sorafenib—PDGFRA—digestive system—pancreatic cancer	0.00021	0.00992	CbGeAlD
Sorafenib—UGT1A1—digestive system—pancreatic cancer	0.000201	0.00947	CbGeAlD
Sorafenib—KIT—pancreas—pancreatic cancer	0.000197	0.00929	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—pancreatic cancer	0.000194	0.000545	CbGbCtD
Sorafenib—PDGFRB—pancreas—pancreatic cancer	0.000192	0.00907	CbGeAlD
Sorafenib—KDR—digestive system—pancreatic cancer	0.00019	0.00895	CbGeAlD
Sorafenib—CSF1R—digestive system—pancreatic cancer	0.000185	0.00874	CbGeAlD
Sorafenib—KIT—digestive system—pancreatic cancer	0.000168	0.00793	CbGeAlD
Sorafenib—PDGFRB—digestive system—pancreatic cancer	0.000164	0.00775	CbGeAlD
Sorafenib—ABCC4—pancreas—pancreatic cancer	0.000153	0.00722	CbGeAlD
Sorafenib—CYP3A5—islet of Langerhans—pancreatic cancer	0.000143	0.00673	CbGeAlD
Sorafenib—ABCC4—digestive system—pancreatic cancer	0.000131	0.00617	CbGeAlD
Sorafenib—HTR2B—digestive system—pancreatic cancer	0.00013	0.00614	CbGeAlD
Sorafenib—ABCC2—digestive system—pancreatic cancer	0.000127	0.00597	CbGeAlD
Sorafenib—CYP2C19—digestive system—pancreatic cancer	0.000109	0.00513	CbGeAlD
Sorafenib—CYP3A5—pancreas—pancreatic cancer	0.0001	0.00473	CbGeAlD
Sorafenib—CDK7—Idarubicin—Epirubicin—pancreatic cancer	9.45e-05	0.0639	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—pancreatic cancer	9.45e-05	0.0639	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—pancreatic cancer	9.45e-05	0.0639	CbGdCrCtD
Sorafenib—CYP1A2—digestive system—pancreatic cancer	8.88e-05	0.00419	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—pancreatic cancer	8.74e-05	0.0591	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—pancreatic cancer	8.74e-05	0.0591	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—pancreatic cancer	8.74e-05	0.0591	CbGdCrCtD
Sorafenib—CYP3A5—digestive system—pancreatic cancer	8.57e-05	0.00404	CbGeAlD
Sorafenib—CYP2B6—digestive system—pancreatic cancer	8.51e-05	0.00402	CbGeAlD
Sorafenib—CYP2C9—digestive system—pancreatic cancer	8.43e-05	0.00398	CbGeAlD
Sorafenib—ABCB1—islet of Langerhans—pancreatic cancer	7.58e-05	0.00358	CbGeAlD
Sorafenib—CYP3A4—digestive system—pancreatic cancer	6.43e-05	0.00303	CbGeAlD
Sorafenib—CYP2D6—digestive system—pancreatic cancer	6.33e-05	0.00299	CbGeAlD
Sorafenib—ABCB1—pancreas—pancreatic cancer	5.33e-05	0.00251	CbGeAlD
Sorafenib—ABCB1—digestive system—pancreatic cancer	4.55e-05	0.00215	CbGeAlD
Sorafenib—Nasopharyngitis—Epirubicin—pancreatic cancer	3.41e-05	0.00051	CcSEcCtD
Sorafenib—Malnutrition—Docetaxel—pancreatic cancer	3.4e-05	0.000509	CcSEcCtD
Sorafenib—Erythema—Docetaxel—pancreatic cancer	3.4e-05	0.000509	CcSEcCtD
Sorafenib—Decreased appetite—Gemcitabine—pancreatic cancer	3.4e-05	0.000509	CcSEcCtD
Sorafenib—Dyspepsia—Fluorouracil—pancreatic cancer	3.39e-05	0.000507	CcSEcCtD
Sorafenib—Nausea—Tamoxifen—pancreatic cancer	3.38e-05	0.000506	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	3.38e-05	0.000506	CcSEcCtD
Sorafenib—Fatigue—Gemcitabine—pancreatic cancer	3.37e-05	0.000505	CcSEcCtD
Sorafenib—Gastritis—Epirubicin—pancreatic cancer	3.37e-05	0.000505	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	3.36e-05	0.000503	CcSEcCtD
Sorafenib—Pain—Gemcitabine—pancreatic cancer	3.35e-05	0.000501	CcSEcCtD
Sorafenib—Constipation—Gemcitabine—pancreatic cancer	3.35e-05	0.000501	CcSEcCtD
Sorafenib—Nausea—Erlotinib—pancreatic cancer	3.35e-05	0.000501	CcSEcCtD
Sorafenib—Decreased appetite—Fluorouracil—pancreatic cancer	3.35e-05	0.000501	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—pancreatic cancer	3.34e-05	0.0005	CcSEcCtD
Sorafenib—Diarrhoea—Sunitinib—pancreatic cancer	3.34e-05	0.0005	CcSEcCtD
Sorafenib—Dysgeusia—Docetaxel—pancreatic cancer	3.33e-05	0.000499	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	3.32e-05	0.000497	CcSEcCtD
Sorafenib—Dysphagia—Epirubicin—pancreatic cancer	3.29e-05	0.000493	CcSEcCtD
Sorafenib—Pain—Fluorouracil—pancreatic cancer	3.29e-05	0.000493	CcSEcCtD
Sorafenib—Gastrointestinal pain—Irinotecan—pancreatic cancer	3.29e-05	0.000492	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—pancreatic cancer	3.28e-05	0.000491	CcSEcCtD
Sorafenib—Muscle spasms—Docetaxel—pancreatic cancer	3.27e-05	0.00049	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—pancreatic cancer	3.23e-05	0.000484	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—pancreatic cancer	3.23e-05	0.000484	CcSEcCtD
Sorafenib—Dizziness—Sunitinib—pancreatic cancer	3.23e-05	0.000483	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—pancreatic cancer	3.22e-05	0.000482	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—pancreatic cancer	3.21e-05	0.000481	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—pancreatic cancer	3.19e-05	0.000477	CcSEcCtD
Sorafenib—Body temperature increased—Irinotecan—pancreatic cancer	3.18e-05	0.000476	CcSEcCtD
Sorafenib—Abdominal pain—Irinotecan—pancreatic cancer	3.18e-05	0.000476	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	3.18e-05	0.000475	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	3.18e-05	0.000475	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—pancreatic cancer	3.15e-05	0.000472	CcSEcCtD
Sorafenib—Anaemia—Docetaxel—pancreatic cancer	3.15e-05	0.000471	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—pancreatic cancer	3.12e-05	0.000467	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	3.11e-05	0.000466	CcSEcCtD
Sorafenib—Vomiting—Sunitinib—pancreatic cancer	3.1e-05	0.000464	CcSEcCtD
Sorafenib—Body temperature increased—Gemcitabine—pancreatic cancer	3.09e-05	0.000463	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—pancreatic cancer	3.08e-05	0.000461	CcSEcCtD
Sorafenib—Rash—Sunitinib—pancreatic cancer	3.08e-05	0.00046	CcSEcCtD
Sorafenib—Dermatitis—Sunitinib—pancreatic cancer	3.07e-05	0.00046	CcSEcCtD
Sorafenib—Urticaria—Fluorouracil—pancreatic cancer	3.06e-05	0.000458	CcSEcCtD
Sorafenib—Headache—Sunitinib—pancreatic cancer	3.06e-05	0.000457	CcSEcCtD
Sorafenib—Syncope—Docetaxel—pancreatic cancer	3.05e-05	0.000457	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—pancreatic cancer	3.05e-05	0.000456	CcSEcCtD
Sorafenib—Leukopenia—Docetaxel—pancreatic cancer	3.05e-05	0.000456	CcSEcCtD
Sorafenib—Body temperature increased—Fluorouracil—pancreatic cancer	3.04e-05	0.000455	CcSEcCtD
Sorafenib—Loss of consciousness—Docetaxel—pancreatic cancer	2.99e-05	0.000448	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—pancreatic cancer	2.99e-05	0.000447	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—pancreatic cancer	2.98e-05	0.000446	CcSEcCtD
Sorafenib—Cough—Docetaxel—pancreatic cancer	2.97e-05	0.000445	CcSEcCtD
Sorafenib—Hypersensitivity—Irinotecan—pancreatic cancer	2.96e-05	0.000443	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—pancreatic cancer	2.95e-05	0.000442	CcSEcCtD
Sorafenib—Hypertension—Docetaxel—pancreatic cancer	2.94e-05	0.00044	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—pancreatic cancer	2.94e-05	0.00044	CcSEcCtD
Sorafenib—Infestation—Epirubicin—pancreatic cancer	2.94e-05	0.00044	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	2.91e-05	0.000436	CcSEcCtD
Sorafenib—Myalgia—Docetaxel—pancreatic cancer	2.9e-05	0.000434	CcSEcCtD
Sorafenib—Arthralgia—Docetaxel—pancreatic cancer	2.9e-05	0.000434	CcSEcCtD
Sorafenib—Nausea—Sunitinib—pancreatic cancer	2.9e-05	0.000434	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—pancreatic cancer	2.89e-05	0.000432	CcSEcCtD
Sorafenib—Asthenia—Irinotecan—pancreatic cancer	2.88e-05	0.000432	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—pancreatic cancer	2.88e-05	0.000431	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	2.88e-05	0.000431	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—pancreatic cancer	2.86e-05	0.000429	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—pancreatic cancer	2.86e-05	0.000429	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—pancreatic cancer	2.85e-05	0.000427	CcSEcCtD
Sorafenib—Hypersensitivity—Fluorouracil—pancreatic cancer	2.84e-05	0.000424	CcSEcCtD
Sorafenib—Dry mouth—Docetaxel—pancreatic cancer	2.83e-05	0.000424	CcSEcCtD
Sorafenib—Asthenia—Gemcitabine—pancreatic cancer	2.81e-05	0.00042	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—pancreatic cancer	2.78e-05	0.000416	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—pancreatic cancer	2.78e-05	0.000416	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—pancreatic cancer	2.77e-05	0.000415	CcSEcCtD
Sorafenib—Pruritus—Gemcitabine—pancreatic cancer	2.77e-05	0.000415	CcSEcCtD
Sorafenib—Infection—Docetaxel—pancreatic cancer	2.76e-05	0.000413	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—pancreatic cancer	2.76e-05	0.000413	CcSEcCtD
Sorafenib—Diarrhoea—Irinotecan—pancreatic cancer	2.75e-05	0.000412	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—pancreatic cancer	2.73e-05	0.000409	CcSEcCtD
Sorafenib—Shock—Docetaxel—pancreatic cancer	2.73e-05	0.000409	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—pancreatic cancer	2.72e-05	0.000408	CcSEcCtD
Sorafenib—Pruritus—Fluorouracil—pancreatic cancer	2.72e-05	0.000408	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—pancreatic cancer	2.72e-05	0.000407	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—pancreatic cancer	2.72e-05	0.000407	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—pancreatic cancer	2.72e-05	0.000407	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—pancreatic cancer	2.7e-05	0.000404	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	2.69e-05	0.000403	CcSEcCtD
Sorafenib—Diarrhoea—Gemcitabine—pancreatic cancer	2.68e-05	0.000401	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—pancreatic cancer	2.67e-05	0.0004	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	2.66e-05	0.000399	CcSEcCtD
Sorafenib—Dizziness—Irinotecan—pancreatic cancer	2.66e-05	0.000398	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—pancreatic cancer	2.65e-05	0.000397	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—pancreatic cancer	2.65e-05	0.000397	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—pancreatic cancer	2.65e-05	0.000397	CcSEcCtD
Sorafenib—Anorexia—Docetaxel—pancreatic cancer	2.65e-05	0.000396	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—pancreatic cancer	2.64e-05	0.000395	CcSEcCtD
Sorafenib—Diarrhoea—Fluorouracil—pancreatic cancer	2.63e-05	0.000394	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—pancreatic cancer	2.6e-05	0.00039	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—pancreatic cancer	2.59e-05	0.000388	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—pancreatic cancer	2.58e-05	0.000387	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	2.57e-05	0.000385	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—pancreatic cancer	2.56e-05	0.000384	CcSEcCtD
Sorafenib—Vomiting—Irinotecan—pancreatic cancer	2.55e-05	0.000382	CcSEcCtD
Sorafenib—Dizziness—Fluorouracil—pancreatic cancer	2.54e-05	0.000381	CcSEcCtD
Sorafenib—Rash—Irinotecan—pancreatic cancer	2.53e-05	0.000379	CcSEcCtD
Sorafenib—Dermatitis—Irinotecan—pancreatic cancer	2.53e-05	0.000379	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	2.53e-05	0.000379	CcSEcCtD
Sorafenib—Headache—Irinotecan—pancreatic cancer	2.52e-05	0.000377	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—pancreatic cancer	2.49e-05	0.000373	CcSEcCtD
Sorafenib—Vomiting—Gemcitabine—pancreatic cancer	2.49e-05	0.000373	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—pancreatic cancer	2.48e-05	0.000371	CcSEcCtD
Sorafenib—Rash—Gemcitabine—pancreatic cancer	2.47e-05	0.000369	CcSEcCtD
Sorafenib—Dermatitis—Gemcitabine—pancreatic cancer	2.47e-05	0.000369	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—pancreatic cancer	2.46e-05	0.000368	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—pancreatic cancer	2.45e-05	0.000367	CcSEcCtD
Sorafenib—Headache—Gemcitabine—pancreatic cancer	2.45e-05	0.000367	CcSEcCtD
Sorafenib—Flushing—Epirubicin—pancreatic cancer	2.45e-05	0.000366	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—pancreatic cancer	2.45e-05	0.000366	CcSEcCtD
Sorafenib—Vomiting—Fluorouracil—pancreatic cancer	2.45e-05	0.000366	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—pancreatic cancer	2.44e-05	0.000366	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—pancreatic cancer	2.44e-05	0.000365	CcSEcCtD
Sorafenib—Rash—Fluorouracil—pancreatic cancer	2.43e-05	0.000363	CcSEcCtD
Sorafenib—Dermatitis—Fluorouracil—pancreatic cancer	2.42e-05	0.000363	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—pancreatic cancer	2.41e-05	0.000361	CcSEcCtD
Sorafenib—Headache—Fluorouracil—pancreatic cancer	2.41e-05	0.000361	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.41e-05	0.000361	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.4e-05	0.000359	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—pancreatic cancer	2.4e-05	0.000359	CcSEcCtD
Sorafenib—Fatigue—Docetaxel—pancreatic cancer	2.39e-05	0.000358	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—pancreatic cancer	2.39e-05	0.000358	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—pancreatic cancer	2.39e-05	0.000358	CcSEcCtD
Sorafenib—Nausea—Irinotecan—pancreatic cancer	2.39e-05	0.000357	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—pancreatic cancer	2.38e-05	0.000357	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—pancreatic cancer	2.38e-05	0.000356	CcSEcCtD
Sorafenib—Constipation—Docetaxel—pancreatic cancer	2.38e-05	0.000356	CcSEcCtD
Sorafenib—Pain—Docetaxel—pancreatic cancer	2.38e-05	0.000356	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—pancreatic cancer	2.36e-05	0.000353	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—pancreatic cancer	2.33e-05	0.000349	CcSEcCtD
Sorafenib—Nausea—Gemcitabine—pancreatic cancer	2.32e-05	0.000348	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—pancreatic cancer	2.31e-05	0.000346	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—pancreatic cancer	2.31e-05	0.000345	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—pancreatic cancer	2.3e-05	0.000344	CcSEcCtD
Sorafenib—Erythema—Epirubicin—pancreatic cancer	2.3e-05	0.000344	CcSEcCtD
Sorafenib—Nausea—Fluorouracil—pancreatic cancer	2.29e-05	0.000342	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—pancreatic cancer	2.27e-05	0.000341	CcSEcCtD
Sorafenib—Gastrointestinal pain—Docetaxel—pancreatic cancer	2.27e-05	0.00034	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—pancreatic cancer	2.26e-05	0.000339	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—pancreatic cancer	2.26e-05	0.000339	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—pancreatic cancer	2.25e-05	0.000337	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—pancreatic cancer	2.21e-05	0.000331	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—pancreatic cancer	2.21e-05	0.00033	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—pancreatic cancer	2.2e-05	0.00033	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.2e-05	0.000329	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—pancreatic cancer	2.2e-05	0.000329	CcSEcCtD
Sorafenib—Body temperature increased—Docetaxel—pancreatic cancer	2.2e-05	0.000329	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—pancreatic cancer	2.18e-05	0.000326	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—pancreatic cancer	2.16e-05	0.000323	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—pancreatic cancer	2.14e-05	0.00032	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—pancreatic cancer	2.12e-05	0.000318	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—pancreatic cancer	2.12e-05	0.000318	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—pancreatic cancer	2.12e-05	0.000318	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—pancreatic cancer	2.08e-05	0.000311	CcSEcCtD
Sorafenib—Syncope—Epirubicin—pancreatic cancer	2.06e-05	0.000308	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—pancreatic cancer	2.05e-05	0.000308	CcSEcCtD
Sorafenib—Hypersensitivity—Docetaxel—pancreatic cancer	2.05e-05	0.000306	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—pancreatic cancer	2.04e-05	0.000306	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—pancreatic cancer	2.02e-05	0.000302	CcSEcCtD
Sorafenib—Cough—Epirubicin—pancreatic cancer	2e-05	0.0003	CcSEcCtD
Sorafenib—Asthenia—Docetaxel—pancreatic cancer	1.99e-05	0.000298	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—pancreatic cancer	1.98e-05	0.000297	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—pancreatic cancer	1.97e-05	0.000294	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—pancreatic cancer	1.96e-05	0.000294	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—pancreatic cancer	1.95e-05	0.000293	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—pancreatic cancer	1.95e-05	0.000293	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	1.94e-05	0.000291	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—pancreatic cancer	1.91e-05	0.000286	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—pancreatic cancer	1.9e-05	0.000285	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—pancreatic cancer	1.9e-05	0.000285	CcSEcCtD
Sorafenib—Diarrhoea—Docetaxel—pancreatic cancer	1.9e-05	0.000285	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—pancreatic cancer	1.87e-05	0.00028	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—pancreatic cancer	1.87e-05	0.000279	CcSEcCtD
Sorafenib—Infection—Epirubicin—pancreatic cancer	1.86e-05	0.000279	CcSEcCtD
Sorafenib—Cough—Doxorubicin—pancreatic cancer	1.85e-05	0.000277	CcSEcCtD
Sorafenib—Shock—Epirubicin—pancreatic cancer	1.84e-05	0.000276	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—pancreatic cancer	1.84e-05	0.000275	CcSEcCtD
Sorafenib—Dizziness—Docetaxel—pancreatic cancer	1.84e-05	0.000275	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—pancreatic cancer	1.83e-05	0.000275	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—pancreatic cancer	1.83e-05	0.000275	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—pancreatic cancer	1.82e-05	0.000272	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—pancreatic cancer	1.81e-05	0.000271	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—pancreatic cancer	1.81e-05	0.000271	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.8e-05	0.000269	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—pancreatic cancer	1.79e-05	0.000267	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—pancreatic cancer	1.77e-05	0.000265	CcSEcCtD
Sorafenib—Vomiting—Docetaxel—pancreatic cancer	1.77e-05	0.000264	CcSEcCtD
Sorafenib—Rash—Docetaxel—pancreatic cancer	1.75e-05	0.000262	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—pancreatic cancer	1.75e-05	0.000262	CcSEcCtD
Sorafenib—Headache—Docetaxel—pancreatic cancer	1.74e-05	0.00026	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—pancreatic cancer	1.73e-05	0.00026	CcSEcCtD
Sorafenib—Infection—Doxorubicin—pancreatic cancer	1.72e-05	0.000258	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	1.71e-05	0.000256	CcSEcCtD
Sorafenib—Shock—Doxorubicin—pancreatic cancer	1.71e-05	0.000255	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—pancreatic cancer	1.7e-05	0.000254	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.7e-05	0.000254	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—pancreatic cancer	1.68e-05	0.000252	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—pancreatic cancer	1.67e-05	0.00025	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—pancreatic cancer	1.65e-05	0.000247	CcSEcCtD
Sorafenib—Nausea—Docetaxel—pancreatic cancer	1.65e-05	0.000247	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—pancreatic cancer	1.65e-05	0.000247	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—pancreatic cancer	1.63e-05	0.000244	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.62e-05	0.000242	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—pancreatic cancer	1.62e-05	0.000242	CcSEcCtD
Sorafenib—Pain—Epirubicin—pancreatic cancer	1.6e-05	0.00024	CcSEcCtD
Sorafenib—Constipation—Epirubicin—pancreatic cancer	1.6e-05	0.00024	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.58e-05	0.000236	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—pancreatic cancer	1.55e-05	0.000231	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.53e-05	0.000229	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—pancreatic cancer	1.53e-05	0.000228	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—pancreatic cancer	1.51e-05	0.000226	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.5e-05	0.000224	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—pancreatic cancer	1.49e-05	0.000224	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—pancreatic cancer	1.49e-05	0.000223	CcSEcCtD
Sorafenib—Pain—Doxorubicin—pancreatic cancer	1.48e-05	0.000222	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—pancreatic cancer	1.48e-05	0.000222	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—pancreatic cancer	1.48e-05	0.000222	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—pancreatic cancer	1.48e-05	0.000222	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.42e-05	0.000212	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—pancreatic cancer	1.38e-05	0.000207	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—pancreatic cancer	1.38e-05	0.000206	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—pancreatic cancer	1.37e-05	0.000205	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—pancreatic cancer	1.37e-05	0.000205	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—pancreatic cancer	1.34e-05	0.000201	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—pancreatic cancer	1.33e-05	0.000198	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—pancreatic cancer	1.28e-05	0.000192	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—pancreatic cancer	1.28e-05	0.000191	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—pancreatic cancer	1.24e-05	0.000186	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—pancreatic cancer	1.24e-05	0.000185	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—pancreatic cancer	1.23e-05	0.000184	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—pancreatic cancer	1.19e-05	0.000178	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—pancreatic cancer	1.19e-05	0.000178	CcSEcCtD
Sorafenib—Rash—Epirubicin—pancreatic cancer	1.18e-05	0.000177	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—pancreatic cancer	1.18e-05	0.000177	CcSEcCtD
Sorafenib—Headache—Epirubicin—pancreatic cancer	1.17e-05	0.000176	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—pancreatic cancer	1.15e-05	0.000172	CcSEcCtD
Sorafenib—Nausea—Epirubicin—pancreatic cancer	1.11e-05	0.000167	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—pancreatic cancer	1.1e-05	0.000165	CcSEcCtD
Sorafenib—Rash—Doxorubicin—pancreatic cancer	1.09e-05	0.000164	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—pancreatic cancer	1.09e-05	0.000163	CcSEcCtD
Sorafenib—Headache—Doxorubicin—pancreatic cancer	1.09e-05	0.000163	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—pancreatic cancer	1.03e-05	0.000154	CcSEcCtD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	6.81e-07	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	6.79e-07	1.08e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GCG—pancreatic cancer	6.79e-07	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	6.75e-07	1.07e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—pancreatic cancer	6.74e-07	1.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.73e-07	1.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—pancreatic cancer	6.71e-07	1.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—pancreatic cancer	6.7e-07	1.07e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	6.69e-07	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—pancreatic cancer	6.69e-07	1.06e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—pancreatic cancer	6.69e-07	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—pancreatic cancer	6.67e-07	1.06e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	6.65e-07	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—pancreatic cancer	6.65e-07	1.06e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—pancreatic cancer	6.64e-07	1.06e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—pancreatic cancer	6.62e-07	1.05e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—pancreatic cancer	6.61e-07	1.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—pancreatic cancer	6.6e-07	1.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—pancreatic cancer	6.6e-07	1.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—pancreatic cancer	6.6e-07	1.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—pancreatic cancer	6.59e-07	1.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—pancreatic cancer	6.59e-07	1.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—pancreatic cancer	6.58e-07	1.05e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—pancreatic cancer	6.58e-07	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	6.57e-07	1.05e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—pancreatic cancer	6.57e-07	1.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—pancreatic cancer	6.55e-07	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	6.51e-07	1.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—pancreatic cancer	6.5e-07	1.03e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—pancreatic cancer	6.48e-07	1.03e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—pancreatic cancer	6.48e-07	1.03e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—pancreatic cancer	6.48e-07	1.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—pancreatic cancer	6.47e-07	1.03e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—pancreatic cancer	6.47e-07	1.03e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—pancreatic cancer	6.47e-07	1.03e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—pancreatic cancer	6.46e-07	1.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—pancreatic cancer	6.43e-07	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—pancreatic cancer	6.42e-07	1.02e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—pancreatic cancer	6.42e-07	1.02e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—STK11—pancreatic cancer	6.38e-07	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	6.38e-07	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	6.34e-07	1.01e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—pancreatic cancer	6.34e-07	1.01e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—pancreatic cancer	6.34e-07	1.01e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—pancreatic cancer	6.31e-07	1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—pancreatic cancer	6.2e-07	9.86e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	6.19e-07	9.85e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—pancreatic cancer	6.18e-07	9.84e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SRC—pancreatic cancer	6.17e-07	9.81e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—pancreatic cancer	6.15e-07	9.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—pancreatic cancer	6.14e-07	9.77e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—pancreatic cancer	6.14e-07	9.76e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—pancreatic cancer	6.14e-07	9.76e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—pancreatic cancer	6.13e-07	9.75e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—pancreatic cancer	6.12e-07	9.74e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	6.11e-07	9.72e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—pancreatic cancer	6.1e-07	9.71e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—pancreatic cancer	6.09e-07	9.69e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—pancreatic cancer	6.08e-07	9.68e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.08e-07	9.67e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—pancreatic cancer	6.08e-07	9.67e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—pancreatic cancer	6.04e-07	9.62e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	6.02e-07	9.58e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—pancreatic cancer	6.02e-07	9.57e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—pancreatic cancer	6.01e-07	9.56e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—pancreatic cancer	6e-07	9.55e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.99e-07	9.53e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—pancreatic cancer	5.99e-07	9.53e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—pancreatic cancer	5.99e-07	9.53e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—pancreatic cancer	5.98e-07	9.52e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—pancreatic cancer	5.97e-07	9.5e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—pancreatic cancer	5.96e-07	9.49e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	5.95e-07	9.46e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—pancreatic cancer	5.95e-07	9.46e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—pancreatic cancer	5.93e-07	9.44e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—pancreatic cancer	5.93e-07	9.43e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—pancreatic cancer	5.93e-07	9.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	5.92e-07	9.42e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—pancreatic cancer	5.9e-07	9.39e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	5.88e-07	9.36e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—pancreatic cancer	5.88e-07	9.36e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—pancreatic cancer	5.85e-07	9.3e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—pancreatic cancer	5.8e-07	9.22e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	5.8e-07	9.22e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—pancreatic cancer	5.78e-07	9.2e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—pancreatic cancer	5.73e-07	9.12e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	5.73e-07	9.12e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	5.69e-07	9.05e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—pancreatic cancer	5.68e-07	9.04e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	5.67e-07	9.03e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—pancreatic cancer	5.67e-07	9.02e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	5.66e-07	9e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	5.65e-07	9e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—pancreatic cancer	5.65e-07	8.98e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—pancreatic cancer	5.6e-07	8.9e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—pancreatic cancer	5.59e-07	8.9e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—pancreatic cancer	5.59e-07	8.9e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—pancreatic cancer	5.53e-07	8.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—pancreatic cancer	5.53e-07	8.79e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—pancreatic cancer	5.51e-07	8.77e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—pancreatic cancer	5.5e-07	8.75e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—pancreatic cancer	5.5e-07	8.75e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—pancreatic cancer	5.5e-07	8.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	5.5e-07	8.75e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—pancreatic cancer	5.49e-07	8.74e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—pancreatic cancer	5.47e-07	8.71e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD44—pancreatic cancer	5.47e-07	8.7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	5.45e-07	8.67e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.43e-07	8.63e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—pancreatic cancer	5.41e-07	8.6e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—pancreatic cancer	5.35e-07	8.52e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—pancreatic cancer	5.32e-07	8.47e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—pancreatic cancer	5.32e-07	8.47e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	5.3e-07	8.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—pancreatic cancer	5.3e-07	8.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—pancreatic cancer	5.29e-07	8.41e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—pancreatic cancer	5.28e-07	8.41e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—pancreatic cancer	5.27e-07	8.39e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—pancreatic cancer	5.27e-07	8.39e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	5.26e-07	8.37e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	5.25e-07	8.35e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	5.25e-07	8.35e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCG—pancreatic cancer	5.24e-07	8.34e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—pancreatic cancer	5.23e-07	8.32e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—pancreatic cancer	5.22e-07	8.31e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—pancreatic cancer	5.21e-07	8.29e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—pancreatic cancer	5.2e-07	8.27e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	5.17e-07	8.23e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	5.16e-07	8.2e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	5.15e-07	8.19e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	5.14e-07	8.18e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—pancreatic cancer	5.14e-07	8.18e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	5.13e-07	8.16e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	5.12e-07	8.14e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—pancreatic cancer	5.11e-07	8.13e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	5.1e-07	8.11e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—pancreatic cancer	5.09e-07	8.1e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—pancreatic cancer	5.09e-07	8.1e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	5.08e-07	8.08e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—pancreatic cancer	5.05e-07	8.04e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	5.05e-07	8.03e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—pancreatic cancer	5.04e-07	8.02e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—pancreatic cancer	4.99e-07	7.94e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	4.99e-07	7.94e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—pancreatic cancer	4.98e-07	7.93e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.95e-07	7.87e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—pancreatic cancer	4.94e-07	7.86e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—STK11—pancreatic cancer	4.93e-07	7.84e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—pancreatic cancer	4.93e-07	7.84e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—pancreatic cancer	4.91e-07	7.82e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—pancreatic cancer	4.88e-07	7.76e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—pancreatic cancer	4.87e-07	7.75e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	4.87e-07	7.75e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—pancreatic cancer	4.83e-07	7.69e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—pancreatic cancer	4.82e-07	7.67e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—pancreatic cancer	4.82e-07	7.67e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.76e-07	7.57e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—pancreatic cancer	4.75e-07	7.55e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	4.72e-07	7.5e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—pancreatic cancer	4.69e-07	7.47e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	4.62e-07	7.35e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.59e-07	7.31e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	4.58e-07	7.28e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	4.57e-07	7.26e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—pancreatic cancer	4.55e-07	7.24e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—pancreatic cancer	4.55e-07	7.24e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	4.55e-07	7.24e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—pancreatic cancer	4.54e-07	7.22e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—pancreatic cancer	4.53e-07	7.21e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—pancreatic cancer	4.49e-07	7.15e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—pancreatic cancer	4.49e-07	7.15e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	4.47e-07	7.12e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—pancreatic cancer	4.47e-07	7.11e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	4.44e-07	7.07e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.44e-07	7.06e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—pancreatic cancer	4.43e-07	7.05e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	4.4e-07	7e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	4.36e-07	6.94e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—pancreatic cancer	4.34e-07	6.91e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—pancreatic cancer	4.33e-07	6.89e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	4.32e-07	6.88e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—pancreatic cancer	4.27e-07	6.79e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—pancreatic cancer	4.25e-07	6.77e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—pancreatic cancer	4.25e-07	6.77e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	4.24e-07	6.75e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.24e-07	6.74e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.23e-07	6.73e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—pancreatic cancer	4.2e-07	6.68e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—pancreatic cancer	4.2e-07	6.68e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	4.18e-07	6.66e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—pancreatic cancer	4.18e-07	6.65e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	4.16e-07	6.62e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	4.15e-07	6.6e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	4.14e-07	6.59e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—pancreatic cancer	4.05e-07	6.44e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.03e-07	6.41e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	3.96e-07	6.31e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	3.93e-07	6.25e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—pancreatic cancer	3.93e-07	6.25e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.89e-07	6.19e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—pancreatic cancer	3.87e-07	6.16e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.87e-07	6.16e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—pancreatic cancer	3.84e-07	6.11e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.83e-07	6.1e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—pancreatic cancer	3.83e-07	6.1e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	3.66e-07	5.82e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.65e-07	5.8e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	3.61e-07	5.75e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.61e-07	5.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.61e-07	5.74e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—pancreatic cancer	3.58e-07	5.7e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—pancreatic cancer	3.56e-07	5.67e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	3.54e-07	5.64e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—pancreatic cancer	3.53e-07	5.62e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—pancreatic cancer	3.49e-07	5.56e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—pancreatic cancer	3.45e-07	5.48e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—pancreatic cancer	3.43e-07	5.45e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—pancreatic cancer	3.42e-07	5.44e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—pancreatic cancer	3.34e-07	5.32e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	3.34e-07	5.31e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	3.2e-07	5.09e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.15e-07	5.01e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	3.13e-07	4.97e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—pancreatic cancer	3.12e-07	4.97e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.11e-07	4.95e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.09e-07	4.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.06e-07	4.87e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—pancreatic cancer	3e-07	4.78e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	2.95e-07	4.69e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.73e-07	4.35e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.71e-07	4.31e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.67e-07	4.25e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—pancreatic cancer	2.61e-07	4.16e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.55e-07	4.06e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.42e-07	3.84e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.38e-07	3.79e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.36e-07	3.76e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.36e-07	3.75e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.22e-07	3.54e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—pancreatic cancer	2.21e-07	3.52e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.2e-07	3.51e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.06e-07	3.28e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.97e-07	3.14e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—pancreatic cancer	1.93e-07	3.07e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.88e-07	3e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.82e-07	2.89e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.8e-07	2.86e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.54e-07	2.45e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.45e-07	2.31e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.19e-07	1.89e-06	CbGpPWpGaD
